Don’t expect much relief from the rising costs of medications to treat diabetes. Just as the costs of generic and brand name diabetes medications continue to rise, the cost of developing and introducing new medications is also on the rise.
“The cost of drug development has been increasing for decades,” said Joseph A. DiMasi, PhD, Director of Economic Analysis at the Tufts Center for the Study of Drug Development at Tufts University. “In terms of diabetes drugs, we’ve seen very large trials and lengthening clinical development times, which would suggest larger than average development costs.”
Dr. DiMasi was one of four presenters to discuss the cost of diabetes medications during a special symposium Friday afternoon at the Scientific Sessions.
The average cost to develop a small molecule or biologic agent, considering failure and time costs, has risen to $2.558 billion, he said. That’s up from an average of $1.044 billion a decade earlier, representing an annual compound growth rate of 8.5 percent.
Drug development costs were part of the decennial Tufts survey Innovation in the Pharmaceutical Industry: New Estimate of R&D Costs.
Drug development costs have risen in part because the rate of drug candidate failures is rising. Other factors that have contributed to rising R&D costs include increased clinical trial size and complexity, more expensive inputs from the medical sector, changing trial design to incorporate health technology assessment data, and testing against active comparators to provide comparative effectiveness data. The total time to approval averaged 128 months, according to the Tufts survey.
Regulatory regimes and reimbursement policies also play a role in rising drug costs, noted Richard E. Pratley, MD, Senior Investigator at the Translational Research Institute for Metabolism and Diabetes, Medical Director of the Florida Hospital Diabetes Institute, and Professor of Medicine at the Sanford-Burnham Medical Research Institute at Lake Nona.
In the United Kingdom, for example, the National Institute for Health and Clinical Excellence limits access and utilization based on specific medical criteria and sets pricing levels. In China, many medications must be paid for out-of-pocket.
In the United States, health plans, unions, employer groups, and other payers negotiate pricing directly with drug manufacturers and use tools such as differential copays and pricing levels to control access and prescribing practices. But the Centers for Medicare and Medicaid Services, one of the largest buyers of prescription medications, is forbidden by law to use its market share to leverage pricing or access. This donut hole forces many Medicare beneficiaries to pay onerous out-of-pocket prices.
“It’s clear that we don’t have a solution to drug pricing in this country,” Dr. Pratley said.
“Other countries think they have solutions and are implementing them. It’s not at all clear that these solutions impact the quality of diabetes care. Limiting access to more costly medications is not determinant of the quality of their diabetes care as measured by the proportion of patients who achieve A1C goals and similar measures.”
The converse is equally true. The United States is the top spender on health care, but higher spending is not a determinant of better outcomes.
“We don’t have health care outcomes proportionate to our health care investments,” Dr. Pratley said. “This might be true as well for diabetes medications. If you have good systems, it makes up for having more limited access to more modern medications.”
Private payers in the United States limit access to insulin, but limited access does not translate into more affordable pricing. The price of both human and analog insulins have skyrocketed in recent years, said Irl B. Hirsch, MD, Professor of Medicine at the University of Washington School of Medicine. As a result, nearly all payers limit access to a single product in each category. Access limitations create safety issues, degrade the quality of care, and increase the costs of care.
“Three years ago, nobody cared if the physician prescribed Humalog or Novolog or Lantus or Levemir,” Dr. Hirsch said. “It was all the same to the payer, and the prescriber could select the agent that was most effective for each patient. Now payers require that we prescribe one agent or the other based solely on price negotiations. And whatever insulin we are prescribing now, we will likely have to change as payers negotiate new contracts with drug makers.”
Switching between Humalog and Novolog rarely poses safety concerns. But Lantus and Levemir are not equivalent. Payers either don’t know that switching between products can create health hazards for patients or don’t care, Dr. Hirsch said.
Mandatory drug switching increases costs at the practice level, he added. So do refill rules that give patients just a 24-hour window before their prior prescription is exhausted. Pricing rules that effectively require patients to use vial insulin rather than insulin pens not only increase the paperwork costs of care, but also expose patients to more potential medication errors because they are not using premeasured doses.
The long-anticipated approval of biosimilar insulins might help reduce future price increases, but will not likely reduce current price levels. One reason is that manufacturers have been steadily increasing the price of all insulins in the U.S. in anticipation of biosimilars. The second reason is that while biosimilar insulins have been promoted as less costly than conventional human insulins, the actual price reductions will be modest.
“My understanding is that the price reduction for biosimilar insulins will not be in the range we have seen with other generic drugs,” said Lutz Heinemann, PhD, from Science & Co. of Düsseldorf, Germany. “That means the 90 percent price reductions we have seen with generic drugs will not be there. We will see 20 percent, 30 percent reductions like we have seen with other biosimilar products. There will be savings with biosimilars, but probably not the huge savings that some people have been hoping for.”
